Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4763746
Max Phase: Preclinical
Molecular Formula: C48H65N11O6
Molecular Weight: 892.12
Molecule Type: Unknown
Associated Items:
ID: ALA4763746
Max Phase: Preclinical
Molecular Formula: C48H65N11O6
Molecular Weight: 892.12
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)c1ccn2ncnc(N[C@H]3CC[C@@H](N4CCN(C(=O)CCC(=O)N5CCC(CCN6CCN(c7ccc8c(c7)C(=O)N(C7CCC(=O)N(C)C7=O)C8=O)CC6)CC5)CC4)CC3)c12
Standard InChI: InChI=1S/C48H65N11O6/c1-32(2)37-17-21-58-44(37)45(49-31-50-58)51-34-4-6-35(7-5-34)54-26-28-57(29-27-54)43(62)13-12-42(61)56-19-15-33(16-20-56)14-18-53-22-24-55(25-23-53)36-8-9-38-39(30-36)47(64)59(46(38)63)40-10-11-41(60)52(3)48(40)65/h8-9,17,21,30-35,40H,4-7,10-16,18-20,22-29H2,1-3H3,(H,49,50,51)/t34-,35+,40?
Standard InChI Key: GDDYLBPIGVZFSF-UKMVIOKASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 892.12 | Molecular Weight (Monoisotopic): 891.5119 | AlogP: 3.69 | #Rotatable Bonds: 12 |
Polar Surface Area: 167.32 | Molecular Species: BASE | HBA: 13 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 17 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.92 | CX Basic pKa: 8.59 | CX LogP: 2.63 | CX LogD: 0.83 |
Aromatic Rings: 3 | Heavy Atoms: 65 | QED Weighted: 0.26 | Np Likeness Score: -1.05 |
1. Degorce SL,Tavana O,Banks E,Crafter C,Gingipalli L,Kouvchinov D,Mao Y,Pachl F,Solanki A,Valge-Archer V,Yang B,Edmondson SD. (2020) Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase., 63 (18): [PMID:32803978] [10.1021/acs.jmedchem.0c01125] |
Source(1):